CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery
December 23, 2021 08:00 ET
|
Centogene NV
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases
October 06, 2021 08:00 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...
CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects
September 29, 2021 17:05 ET
|
CENTOGENE GmbH
Collaborative research utilized insights gained from CENTOGENE’s rare disease-centric Bio/Databank to help analyze data of more than 20,000 familiesEnabled testing of successful targeted therapeutic...
CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021
September 01, 2021 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development
July 27, 2021 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 27, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting
June 25, 2021 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 25, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years
June 22, 2021 06:30 ET
|
CENTOGENE GmbH
Company outlines significant value creation potential to contribute to the diagnosis of rare diseases and to enable the development of novel therapeuticsFocuses on leveraging its unique rare...
CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event
June 16, 2021 06:30 ET
|
CENTOGENE GmbH
Recorded revenues of €65.0 million in Q1 2021, driven by revenues from COVID-19 testing, up over 400% compared to €12.1 million in Q1 2020Achieved positive adjusted EBITDA, driven by COVID-19 testing...
CENTOGENE Announces Virtual Investor Event
June 07, 2021 06:30 ET
|
CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 07, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose,...
CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution
June 01, 2021 06:30 ET
|
CENTOGENE GmbH
World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient casesNEW CentoXome® provides...